公司股票及其可转换公司债券于2025年1月6日(星期一)开市起停牌一天，于2025年1月7日(星期二)开市起复牌;公司股票自2025年1月7日开市起被实施“退市风险警示”，公司股票简称：由“普利制药”变更为“*ST普利”，股票代码仍为“300630”;实施退市风险警示后公司股票交易的日涨跌幅限制仍为20%。Hainan Poly Pharm (300630.SZ) issued an announcement that the company is suspected of illegal information disclosure and has been investigated by the China Securities Regulatory Commission.
According to the Zhiyun Finance APP, Hainan Poly Pharm (300630.SZ) announced that the company is being investigated by the China Securities Regulatory Commission for suspected violations of information disclosure laws and regulations. The company received the "Notice of Administrative Penalty" issued by the China Securities Regulatory Commission on January 4, 2025.
According to the facts established in the "Notice", the company's annual reports for 2021 and 2022 contained false records. The total amount of the falsely reported revenue for 2021 and 2022 reached 1,030,503,262.28 yuan, accounting for 31.08% of the total revenue disclosed in the two years; the total amount of falsely reported profit reached 695,435,693.01 yuan, accounting for 76.72% of the total profit disclosed in the two years. Based on the aforementioned facts established in the "Notice", the company may have violated item (1) of Article 10.5.1 and item (7) of Article 10.5.2 of the "Shenzhen Stock Exchange GEM Stocks Listing Rules (2024 Revised)" which stipulates that "if the company's disclosed total profit has false records for two consecutive years, and the total amount of falsely recorded profit exceeds 0.5 billion yuan and is more than 50% of the total profit disclosed for those two years," the company may face mandatory delisting due to significant violations, which could result in the company’s stocks being subjected to major legal mandatory delisting.
The company's stocks and its Convertible Bonds will be suspended from trading for one day starting from January 6, 2025 (Monday) and will resume trading on January 7, 2025 (Tuesday); starting from January 7, 2025, the company's stocks will be subject to "Delisting Risk Warning". The stock abbreviation will change from "Hainan Poly Pharm" to "*ST Hainan Poly", while the stock code remains "300630"; after the implementation of the delisting risk warning, the daily price fluctuation limit for trading the company's stocks will remain at 20%.
According to the "Shenzhen Stock Exchange Stock Listing Rules", if a formal penalty decision concludes that the company involves significant illegal mandatory delisting, the company's stocks will be terminated from listing. According to the "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 15 - Convertible Bonds", if the listed company’s stocks are terminated from listing, the Convertible Bonds will also be terminated from listing or quotation.
